blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2950819

EP2950819 - INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS COMPRISING TOLL-LIKE RECEPTOR AGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.02.2019
Database last updated on 10.08.2024
FormerThe patent has been granted
Status updated on  23.02.2018
FormerGrant of patent is intended
Status updated on  04.01.2018
FormerExamination is in progress
Status updated on  18.11.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
GlaxoSmithKline Biologicals SA
Rue de l'Institut 89
1330 Rixensart / BE
[2015/50]
Inventor(s)01 / GALLORINI, Simona
Novartis Vaccines and Diagnostics S.r.l.
Via Fiorentina 1
I-53100 Siena / IT
02 / BAUDNER, Barbara
Novartis Vaccines and Diagnostics S.r.l
Via Fiorentina 1
I-53100 Siena / IT
03 / O'HAGAN, Derek
Novartis Vaccines and Diagnostics,Inc
350 Massachusetts Avenue
Cambridge Massachusetts 02139 / US
 [2015/50]
Representative(s)Dalton, Marcus Jonathan William
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[2015/50]
Application number, filing date14704537.130.01.2014
[2015/50]
WO2014EP51860
Priority number, dateUS201361759751P01.02.2013         Original published format: US 201361759751 P
EP2013016959628.05.2013         Original published format: EP 13169596
[2015/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014118305
Date:07.08.2014
Language:EN
[2014/32]
Type: A1 Application with search report 
No.:EP2950819
Date:09.12.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 07.08.2014 takes the place of the publication of the European patent application.
[2015/50]
Type: B1 Patent specification 
No.:EP2950819
Date:28.03.2018
Language:EN
[2018/13]
Search report(s)International search report - published on:EP07.08.2014
ClassificationIPC:A61K39/39, A61K39/02, A61K39/095, A61K9/00
[2017/51]
CPC:
A61K39/39 (EP,US); A61K9/0021 (US); A61K39/095 (US);
A61K39/145 (US); C12N7/00 (US); A61K2039/545 (EP,US);
A61K2039/55511 (US); A61K2039/55544 (EP,US); A61K2039/55572 (EP,US);
A61K2039/55583 (EP,US); C12N2760/16134 (US); C12N2760/16171 (US) (-)
Former IPC [2015/50]A61K39/39
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/50]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:INTRADERMALE ABGABE VON IMMUNOLOGISCHEN ZUSAMMENSETZUNGEN MIT TOLL-LIKE-REZEPTOR-AGONISTEN[2015/50]
English:INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS COMPRISING TOLL-LIKE RECEPTOR AGONISTS[2015/50]
French:ADMINISTRATION INTRADERMIQUE DE COMPOSITIONS IMMUNOLOGIQUES COMPRENANT DES AGONISTES DES RÉCEPTEURS DE TYPE TOLL[2015/50]
Entry into regional phase28.08.2015National basic fee paid 
28.08.2015Designation fee(s) paid 
28.08.2015Examination fee paid 
Examination procedure28.08.2015Examination requested  [2015/50]
01.04.2016Amendment by applicant (claims and/or description)
21.07.2016Despatch of a communication from the examining division (Time limit: M06)
12.01.2017Reply to a communication from the examining division
02.03.2017Despatch of a communication from the examining division (Time limit: M06)
02.08.2017Reply to a communication from the examining division
07.09.2017Despatch of a communication from the examining division (Time limit: M04)
02.10.2017Reply to a communication from the examining division
05.01.2018Communication of intention to grant the patent
13.02.2018Fee for grant paid
13.02.2018Fee for publishing/printing paid
13.02.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.07.2016
Opposition(s)03.01.2019No opposition filed within time limit [2019/10]
Fees paidRenewal fee
08.01.2016Renewal fee patent year 03
09.01.2017Renewal fee patent year 04
08.01.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.01.2014
AL28.03.2018
AT28.03.2018
CY28.03.2018
CZ28.03.2018
DK28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
MC28.03.2018
MK28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SI28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
IS28.07.2018
PT30.07.2018
[2022/31]
Former [2021/32]HU30.01.2014
AL28.03.2018
AT28.03.2018
CY28.03.2018
CZ28.03.2018
DK28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
MC28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SI28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
IS28.07.2018
PT30.07.2018
Former [2021/31]AL28.03.2018
AT28.03.2018
CY28.03.2018
CZ28.03.2018
DK28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
MC28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SI28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
IS28.07.2018
PT30.07.2018
Former [2021/26]AL28.03.2018
AT28.03.2018
CY28.03.2018
CZ28.03.2018
DK28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
MC28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SI28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
PT30.07.2018
Former [2019/40]AL28.03.2018
AT28.03.2018
CZ28.03.2018
DK28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
MC28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SI28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
PT30.07.2018
Former [2019/26]AL28.03.2018
AT28.03.2018
CZ28.03.2018
DK28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SI28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
PT30.07.2018
Former [2019/10]AL28.03.2018
AT28.03.2018
CZ28.03.2018
DK28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
PT30.07.2018
Former [2019/08]AL28.03.2018
CZ28.03.2018
DK28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
PT30.07.2018
Former [2019/03]AL28.03.2018
CZ28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
PT30.07.2018
Former [2018/52]AL28.03.2018
CZ28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SK28.03.2018
SM28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
Former [2018/50]AL28.03.2018
CZ28.03.2018
EE28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
PL28.03.2018
RO28.03.2018
RS28.03.2018
SE28.03.2018
SK28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
Former [2018/46]AL28.03.2018
FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
RS28.03.2018
SE28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
Former [2018/40]FI28.03.2018
HR28.03.2018
LT28.03.2018
LV28.03.2018
RS28.03.2018
SE28.03.2018
BG28.06.2018
NO28.06.2018
GR29.06.2018
Former [2018/35]FI28.03.2018
HR28.03.2018
LT28.03.2018
NO28.06.2018
Cited inInternational search[Y]WO02085446  (ALZA CORP [US]) [Y] 1,8-11 * page 3, paragraph 0009 - page 5, paragraph 00013 * * page 9, paragraph 00033 - page 12, paragraph 00039; example -; claim - *;
 [Y]WO2011151723  (NOVARTIS AG [CH], et al) [Y] 1,8-11 * page 7, line 1 - page 8, line 29 * * page 11, line 24 - line 28 * * page 20, line 25 - line 32 *;
 [X]  - PATTANI ADITYA ET AL, "Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations", JOURNAL OF CONTROLLED RELEASE, (201209), vol. 162, no. 3, pages 529 - 537, XP002715004 [X] 1,9-11 * page 529, column r, paragraph 1 - page 530, column l, paragraph 1 * * page 530, column r, paragraph 2 * * page 534, column l, paragraph 2 - page 535, column r, paragraph 1 * * page 536, column l, paragraph l *

DOI:   http://dx.doi.org/10.1016/j.jconrel.2012.07.039
 [X]  - DEMUTH P ET AL, "Engineered microneedle arrays for transcutaneous HIV vaccine delivery", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, (20120913), vol. 9, no. Suppl 2, doi:10.1186/1742-4690-9-S2-P334, ISSN 1742-4690, page P334, XP021116574 [X] 1,11 * the whole document *

DOI:   http://dx.doi.org/10.1186/1742-4690-9-S2-P334
 [XP]  - GUO LEI ET AL, "Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant", INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON), (201304), vol. 447, no. 1-2, pages 22 - 30, XP002715005 [XP] 1,9 * page 22, column r, paragraph 2 - page 23, column l, paragraph 1 * * page 23, column l, paragraph 4 * * page 24, column l, paragraph 3 - column r, paragraph 3 * * page 28, column r, paragraph 2 - page 29, column l, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2013.02.006
 [A]  - ELSA E KIS ET AL, "Devices for intradermal vaccination", VACCINE, ELSEVIER LTD, GB, vol. 30, no. 3, doi:10.1016/J.VACCINE.2011.11.020, ISSN 0264-410X, (20111106), pages 523 - 538, (20111111), XP028348164 [A] 1,8-11 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2011.11.020
ExaminationUS2011053893
    - WELDON WILLIAM C ET AL, "Effect of Adjuvants on Responses to Skin Immunization by Microneedles Coated with Influenza Subunit Vaccine", PLOS ONE, (201207), vol. 7, no. 7, ISSN 1932-6203(print), page Article No.: e41501
    - MITSUI HIROSHI ET AL, "Differential expression and function of Toll-like receptors in Langerhans cells: Comparison with splenic dendritic cells.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, (200401), vol. 122, no. 1, ISSN 0022-202X, pages 95 - 102
    - SUZUKI HIROTAKE ET AL, "Imiquimod, a topical immune response modifier, induces migration of Langerhans cells", JOURNAL OF INVESTIGATIVE DERMATOLOGY, (200001), vol. 114, no. 1, doi:doi:10.1046/j.1523-1747.2000.00833.x, ISSN 0022-202X, pages 135 - 141, XP002964631

DOI:   http://dx.doi.org/10.1046/j.1523-1747.2000.00833.x
by applicantUS4057685
 US4356170
 US4459286
 EP0208375
 US4663160
 US4666886
 US4673574
 US4695624
 US4761283
 US4808700
 US4882317
 GB2220211
 EP0372501
 EP0378881
 US4965338
 WO9101146
 EP0427347
 EP0471177
 WO9313202
 WO9317712
 WO9403208
 EP0594610
 WO9517211
 WO9737026
 WO9743303
 WO9818931
 WO9818930
 WO9818928
 WO9858668
 WO9924578
 WO9927109
 WO9936544
 US5936076
 WO9953940
 WO9957280
 WO9958562
 WO0006737
 WO0006738
 WO0010599
 WO0012689
 WO0012131
 WO0033882
 WO0037105
 WO0037494
 WO0056360
 WO0058475
 WO0061761
 WO0076540
 WO0112219
 WO0170955
 WO0172337
 WO0181380
 WO0202606
 WO0208426
 WO0218595
 WO0222167
 WO0222168
 WO0234773
 WO0234771
 WO02059148
 WO02077183
 WO02079241
 WO02079243
 WO02091998
 WO02094851
 WO02094868
 WO02102829
 WO03011899
 WO03011223
 WO03049762
 WO03068811
 WO03082183
 WO03093306
 WO03097091
 WO03104272
 WO03105769
 US6699703
 WO2004041157
 US6800744
 WO2004092360
 WO2004092209
 WO2005002619
 WO2005032582
 WO2005079315
 US2005192248
 US6945952
 US2005215517
 WO2005102049
 WO2006032475
 WO2006032472
 WO2006032500
 WO2007000343
 US7182747
 WO2007030477
 WO2007040840
 US7211062
 WO2007053455
 WO2007059289
 WO2007061964
 WO2007113222
 WO2007113223
 WO2007113224
 WO2007116322
 WO2007120362
 WO2007124393
 WO2007127976
 WO2008005555
 WO2008019162
 WO2008047174
 WO2008047249
 WO2009040548
 WO2009067081
 US2009182306
 WO2009111337
 WO2009118296
 WO2010014913
 US2010143301
 EP2289843
 WO2011049677
 US2011112509
 WO2011119759
 WO2012031140
    - REAP ET AL., VACCINE, (2007), vol. 25, pages 7441 - 7449
    - LEMIEUX ET AL., INFECT. IMM., (2006), vol. 74, pages 2453 - 2456
    - HOSKINS ET AL., J. BACTERIOL., (2001), vol. 183, pages 5709 - 5717
    - ADAMOU ET AL., INFECT. IMMUN., (2001), vol. 69, no. 2, pages 949 - 958
    - BRILES ET AL., J. INFECT. DIS., (2000), vol. 182, pages 1694 - 1701
    - TALKINGTON ET AL., MICROB. PATHOG., (1996), vol. 21, no. 1, pages 17 - 22
    - BETHE ET AL., FEMS MICROBIOL. LETT., (2001), vol. 205, no. 1, pages 99 - 104
    - BROWN ET AL., INFECT. IMMUN., (2001), vol. 69, pages 6702 - 6706
    - WHALEN ET AL., FEMS IMMUNOL. MED. MICROBIOL., (2005), vol. 43, pages 73 - 80
    - JOMAA ET AL., VACCINE, (2006), vol. 24, no. 24, pages 5133 - 5139
    - DALE, VACCINE, (1999), vol. 17, pages 193 - 200
    - DALE, VACCINE, vol. 14, no. 10, pages 944 - 948
    - ZHU ET AL., VACCINE, (2004), vol. 22, pages 660 - 669
    - PRICE ET AL., INFECTION AND IMMUNITY, (2004), vol. 71, no. 1, pages 277 - 283
    - PLANTE, J INFECTIOUS DISEASE, (2000), vol. 182, pages 848 - 855
    - PRAUSNITZ ET AL., CURR TOP MICROBIOLIMMUNOL., (2009), vol. 333, pages 369 - 93
    - KANG ET AL., EXPERT REV VACCINES, (2012), vol. 11, no. 5, pages 547 - 60
    - DAVIDSON ET AL., CHEMICAL ENGINEERING RESEARCH AND DESIGN, (2008), vol. 86, pages 1196 - 1206
    - CAREY ET AL., PLOS ONE, (2011), vol. 6, no. 7, page E22442
    - BAL ET AL., J CONTROL RELEASE, (2010), vol. 147, pages 218 - 24
    - DONNELLY ET AL., PHARM RES, (2011), vol. 28, pages 41 - 57
    - KOUTSONANOS ET AL., PLOS ONE, (2009), vol. 4, no. E, page E4773
    - QUAN ET AL., PLOS ONE, (2009), vol. 4, no. 9, page E7152
    - MATSUO ET AL., J CONTROL RELEASE, (2012), vol. 161, pages 10 - 17
    - LEE ET AL., BIOMATERIALS, (2008), vol. 29, no. 13, pages 2113 - 24
    - SULLIVAN ET AL., NATURE MED, (2010), vol. 16, pages 915 - 920
    - OH ET AL., 2006 Annual Meeting and Exposition. TheAAPSJournal, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS, (2006), vol. 8, page 2
    - MATSUO ET AL., J CONTROL RELEASE, (2012), vol. 160, no. 3, pages 495 - 501
    - KOUTSONANOS ET AL., SCI REP., (2012), vol. 2, page 357
    - GILL; PRAUSNITZ, J CONTROL RELEASE, (2007), vol. 117, pages 227 - 37
    - JIN ET AL., BIOMED MICRODEVICES, (2009), vol. 11, no. 6, pages 1195 - 203
    - VRDOLJAK ET AL., J CONTROL RELEASE, (2012), vol. 159, pages 34 - 42
    - ROSENBERG ET AL., J IMMUNOL, (2010), vol. 184, page 136.20
    - MYERS ET AL., CELLULAR AND MOLECULAR ASPECTS OF ENDOTOXIN REACTIONS, (1990), pages 145 - 156
    - JOHNSON ET AL., JMED CHEM, (1999), vol. 42, pages 4640 - 9
    - BALDRICK ET AL., REGULATORY TOXICOL PHARMACOL, (2002), vol. 35, pages 398 - 413
    - COLER ET AL., PLOS ONE, (2011), vol. 6, no. 1, page E16333
    - JOHNSON ET AL., BIOORG MED CHEM LETT, (1999), vol. 9, pages 2273 - 2278
    - EVANS ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 219 - 229
    - BAZIN ET AL., TETRAHEDRON LETT, (2006), vol. 47, pages 2087 - 92
    - WONG ET AL., J CLIN PHARMACOL, (2003), vol. 43, no. 7, pages 735 - 42
    - DE LIBERO ET AL., NATURE REVIEWS IMMUNOLOGY, (2005), vol. 5, pages 485 - 496
    - OKI ET AL., J. CLIN. INVESTIG., vol. 113, pages 1631 - 1640
    - YANG ET AL., ANGEW. CHEM. INT. ED., (2004), vol. 43, pages 3818 - 3822
    - GOFF ET AL., J. AM. CHEM., SOC., (2004), vol. 126, pages 13602 - 13603
    - PEPPOLONI ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 285 - 93
    - DA HORA ET AL., VACCINE, (2011), vol. 29, pages 1538 - 44
    - PIZZA ET AL., INT JMED MICROBIAL, (2000), vol. 290, pages 455 - 61
    - FENG ET AL., ACTA BIOCHIM BIOPHYS SIN (SHANGHAI)., (2005), vol. 37, no. 2, pages 126 - 32
    - TREANOR ET AL., J INFECT DIS, (1996), vol. 173, pages 1467 - 70
    - KEITEL ET AL., CLIN DIAGN LAB IMMUNOL, (1996), vol. 3, pages 507 - 10
    - GIULIANI ET AL., PROC NATL ACAD SCI USA., (2006), vol. 103, pages 10834 - 9
    - CASSONE; TOROSANTUCCI, EXPERT REV VACCINES, (2006), vol. 5, pages 859 - 67
    - RESEARCH DISCLOSURE, (200201), page 453077
    - FALUGI ET AL., EUR J IMMUNOL, (2001), vol. 31, pages 3816 - 3824
    - BARALDO ET AL., INFECT IMMUN, (2004), vol. 72, no. 8, pages 4884 - 7
    - RUAN ET AL., J IMMUNOL, (1990), vol. 145, pages 3379 - 3384
    - KUO ET AL., INFECT IMMUN, (1995), vol. 63, pages 2706 - 13
    - MICHON ET AL., VACCINE, (1998), vol. 16, pages 1732 - 41
    - MOL. IMMUNOL., (1985), vol. 22, pages 907 - 919
    - BETHELL G.S. ET AL., J. BIOL. CHEM., (1979), vol. 254, pages 2572 - 4
    - HEAM M.T.W., J. CHROMATOGR., (1981), vol. 218, pages 509 - 18
    - GEVER ET AL., MED. MICROBIOL. IMMUNOL, (1979), vol. 165, pages 171 - 288
    - TRITTO ET AL., J. IMMUNOL., (2007), vol. 179, pages 5346 - 5357
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.